Technology Transactions and Licensing TRANSACTIONAL

WilmerHale's Technology Transactions and Licensing lawyers leverage technical knowledge, business acumen and legal experience to structure, prepare and negotiate innovative and effective technology-related agreements.


In the highly competitive worlds of biotechnology and information technology, licensing transactions and strategic alliances can make the difference between success and failure. The attorneys in WilmerHale's Technology Transactions and Licensing Practice—many of whom have backgrounds in computer engineering, biochemistry, and other technical fields—collaborate closely with our corporate, licensing, intellectual property, regulatory and tax lawyers to negotiate agreements for clients across a broad spectrum of industries. They handle hundreds of complex joint ventures, strategic alliances, and outsourcing and licensing transactions each year, some of which span international borders. Their work often receives industry commendation for its significance in shaping the future of science and technology.

Contacts

Sort By
Barrett, Steven D.

Steven D. Barrett

Co-Chair, Technology Transactions and Licensing Practice Group

+1 617 526 6238 (t)

steven.barrett@wilmerhale.com

Juran, Belinda M.

Belinda M. Juran

Co-Chair, Technology Transactions and Licensing Practice Group

Co-Chair, Life Sciences Group

+1 617 526 6987 (t)

belinda.juran@wilmerhale.com

Barrett, Steven D.

Steven D. Barrett

Partner

+1 617 526 6238 (t)

steven.barrett@wilmerhale.com

Braun, Martin

Dr. Martin Braun

Partner

+49 69 27 10 78 207 (t)

martin.braun@wilmerhale.com

Finkel, Robert M.

Robert M. Finkel

Partner

+1 212 295 6555 (t)

robert.finkel@wilmerhale.com

Gokhale, Ashwin

Ashwin Gokhale

Partner

+1 650 858 6071 (t)

ashwin.gokhale@wilmerhale.com

Juran, Belinda M.

Belinda M. Juran

Partner

+1 617 526 6987 (t)

belinda.juran@wilmerhale.com

Khorana, Adit

Adit Khorana

Partner

+1 650 858 6164 (t)

adit.khorana@wilmerhale.com

Kipnis, Jason

Jason D. Kipnis

Partner

+1 650 600 5036 (t)

jason.kipnis@wilmerhale.com

Schubert, Klaus

Klaus Schubert

Partner

+49 30 20 22 65 56 (t)

klaus.schubert@wilmerhale.com

Experience

We represent market leaders in life sciences, technology, energy and cleantech, communications, financial services and other industries. These companies include: 

  • Cutting-edge biotech developers Agios, Epizyme, Macrogenics, Merrimack, Ophthotech and Vedanta;
  • Gene-therapy innovators Spark Therapeutics and Editas;
  • Pharmaceutical companies Bristol-Myers Squibb and Vertex;
  • Personalized medicine company Kew Group;
  • Consumer electronics companies Bose and TiVo;
  • Data analysis pioneers Cellebrite, Kensho and Thasos;
  • FinTech innovators MineralTree and Qapital, as well as financial services providers American Express and MFS Investment Management;
  • Hardware developers and manufacturers Analog Devices and SanDisk;
  • Software and IT developers Toyota InfoTechnology Center and Progress Software;
  • Telecommunications leaders Altiostar, Broadcom and Cincinnati Bell;
  • Healthcare IT innovator Caradigm;
  • Video game developer Harmonix;
  • Artificial intelligence developer MetaMind Entertainment; and
  • Filmmaking and technology company Wymsee.

Read more about the transactions we've done.

Publications & News

View

November 17, 2016

Rise of digital DNA raises biopiracy fears

Bruce Manheim is quoted in this article published in Science magazine. The article describes how the use of digital DNA may be regulated by various nations under the Nagoya Protocol and may lead to allegations of biopiracy.

November 11, 2016

WilmerHale Advises Memorial Sloan Kettering, The Rockefeller University and Weill Cornell Medicine in Establishment of Bridge Medicines

Memorial Sloan Kettering Cancer Center, The Rockefeller University and Weill Cornell Medicine announced that they established a new drug discovery company called Bridge Medicines.

November 8, 2016

Regulation of Synthetic Biology Under the Nagoya Protocol

An article by Bruce Manheim, published in Nature Biotechnology, considers whether digital sequence information from genetic resources in foreign countries will be subject to the access and benefit-sharing requirements of the Nagoya Protocol and other international agreements.

October 20, 2016

Banking Regulators Release Advanced Notice of Proposed Rulemaking on Enhanced Cyber Risk Management Standards

The agencies are considering establishing two tiers of enhanced standards—basic enhanced standards for all covered firms and even more stringent enhanced standards for systems that are "sector-critical."

October 13, 2016

WilmerHale Reps Ocular Therapeutix™ in Strategic Collaboration With Regeneron

Ocular Therapeutix, Inc., a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye, announced that it has entered into a strategic collaboration, option and license agreement with Regeneron Pharmaceuticals, Inc.

October 12, 2016

Freedom to Utilize Genetic Resources? The Nagoya Protocol Two Years Later

An article by Bruce Manheim, published as a WilmerHale Client Alert and republished by Intellectual Property Watch, discusses the Nagoya Protocol and how over the past two years—as various nations have adopted new provider and user measures—the Protocol's legal framework has begun to coalesce into an international regulatory scheme governing access to and use of genetic resources for research and development.

October 4, 2016

Sarepta Therapeutics and Summit Enter into Exclusive License and Collaboration Agreement

WilmerHale client Summit Therapeutics plc and Sarepta Therapeutics announced that they have entered into an exclusive license and collaboration agreement granting Sarepta rights in Europe, as well as in Turkey and the Commonwealth of Independent States.

August 17, 2016

WilmerHale Reps Eleven Biotherapeutics in License Agreement with Roche for Antagonist Antibody Technology

WilmerHale represented Eleven Biotherapeutics, a biopharmaceutical company researching and developing protein therapeutics to treat diseases of the eye, in the negotiation of a license agreement with Roche for Eleven's IL-6 antagonist monoclonal antibody program, including its preclinical ophthalmic drug EBI-031.

June 22, 2016

The Legal 500 United States 2016 Recognizes 111 WilmerHale Lawyers Across 30 Practice Areas

The guide's rankings are based on a series of criteria, including client feedback, interviews with private practice lawyers, and its own research.

May 27, 2016

WilmerHale Lawyers and Practices Recognized in 2016 Edition of Chambers USA

Chambers USA: America's Leading Lawyers for Business announced its final rankings for the 2016 edition, with WilmerHale ranking among the nation's best in 47 practice area categories. Chambers also ranked 82 WilmerHale lawyers as leaders in their respective fields.

Recognition

  • Best Lawyers in America – Recognized nearly 100 WilmerHale partners in 2016, naming seven as Lawyers of the Year. From 2010-2013, WilmerHale's Technology Law practice received a number one ranking.
  • BioPharm Insight – Consistently lists our attorneys among the leading legal advisors for biotech and pharma licensing agreements in the global, North American and European and Asia-Pacific ranking tables.
  • Chambers Global – Named WilmerHale among the best in the United States in outsourcing in 2014 and 2015.
  • Chambers USA: America's Leading Lawyers for Business – Named the firm in 2016 among the best in Massachusetts in technology, and in 2014 and 2015 among the best in the nation in technology and outsourcing. The "enormously respected" Robert Finkel is recognized for his significant technology experience and "practical approach and negotiation style." He is also named a "thought leader in the sourcing industry" with "unparalleled" industry knowledge.
  • LMG Life Sciences Ranked the firm in its 2013-2016 editions in the areas of patent prosecution, patent strategy and management, general patent litigation, Hatch-Waxman patent litigation, corporate, licensing and collaboration, M&A, venture capital and white collar/government investigations. The firm was also named a "Lifecycle Firm," meaning the firm is regarded as one of the best full-service law firms serving the life sciences industry. Co-Chairs Steven Barrett and Belinda Juran have also been named "Life Sciences Stars." 
  • Super Lawyers – Named Co-Chair Steven Barrett a "Massachusetts Super Lawyer" in the 2014 edition of Boston Magazine.
  • The Legal 500 United States – Recognized Co-Chair Belinda Juran in 2013 as "a fantastic collaborator" and "outstanding in licensing."
  • U.S. News - Best Lawyers® – In the 2017 "Best Law Firms" rankings, our technology law practice was ranked in the second-tier nationally and in the first-tier in Boston. Our information technology law practice was ranked in the third-tier nationally and second-tier in Boston.
  • Who's Who Legal – Recognized Co-Chair Steven Barrett as a leader in life sciences in the 2015 edition.